Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Grant
A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator's Choice in Previously Untreated
Active
$7.5M Funding
3 People
External
Related Topics
immunotherapy,
cancer treatment,
biopharmaceuticals,
clinical trials,
monoclonal antibodies
People
Abhijeet Kumar
Principal Investigator (PI)
Medicine
﹒Associate Professor, Medicine - (Clinical Scholar Track)
Michele Holland
(CD)
Cancer Center Division
﹒Research Compliance Administrator II
Bital Savir-Baruch
Co-Investigator (COI)
Medical Imaging
﹒Professor